Treatment of Severe Clostridioides difficile Infection
For severe C. difficile infection (defined as WBC ≥15,000 cells/μL OR serum creatinine >1.5 mg/dL), treat with either vancomycin 125 mg orally four times daily for 10 days OR fidaxomicin 200 mg twice daily for 10 days 1.
Defining Severe vs. Fulminant Disease
You must first distinguish between severe and fulminant CDI, as treatment differs significantly:
Severe CDI is characterized by:
- White blood cell count ≥15,000 cells/μL, OR
- Serum creatinine >1.5 mg/dL
Fulminant CDI presents with:
- Hypotension or shock
- Ileus
- Megacolon
This distinction is critical because fulminant disease requires escalated therapy and surgical consultation 1.
Treatment Algorithm for Severe (Non-Fulminant) CDI
First-line options (both have strong recommendation, high-quality evidence):
- Vancomycin 125 mg orally four times daily for 10 days, OR
- Fidaxomicin 200 mg twice daily for 10 days 1
The 2021 IDSA/SHEA focused update maintains these recommendations, with fidaxomicin preferred when resources allow, though vancomycin remains an acceptable alternative 2.
Critical Management Points
Discontinue the inciting antibiotic immediately if clinically feasible—this directly impacts recurrence risk (strong recommendation) 1.
Do NOT use metronidazole for severe CDI. Metronidazole is only acceptable for nonsevere disease when vancomycin or fidaxomicin are unavailable, and carries risk of cumulative neurotoxicity with repeated courses 1.
Treatment for Fulminant CDI
For fulminant disease, escalate to high-dose vancomycin 500 mg orally four times daily PLUS intravenous metronidazole 500 mg every 8 hours (strong recommendation for oral vancomycin, strong recommendation for IV metronidazole) 1.
Additional Interventions for Fulminant Disease
If ileus is present:
- Add rectal vancomycin 500 mg in approximately 100 mL normal saline every 6 hours as a retention enema (weak recommendation, but important when oral route compromised) 1
- Continue IV metronidazole as oral absorption is unreliable 1
Obtain surgical consultation early (within 3-5 days if no improvement) for potential total colectomy or loop ileostomy with colonic lavage 3, 4, 5. Delaying surgical intervention in fulminant cases increases mortality.
Common Pitfalls to Avoid
Using the same 125 mg vancomycin dose for fulminant disease—you must escalate to 500 mg four times daily for fulminant CDI 1
Relying on IV vancomycin—it does not achieve adequate colonic concentrations and should never be used for CDI treatment 1
Continuing metronidazole monotherapy in severe disease—this is no longer recommended and associated with worse outcomes 6, 7
Delaying surgical consultation—if the patient deteriorates or fails to improve within 3-5 days despite maximal medical therapy, surgery should be considered urgently 3, 4, 5
Monitoring and Response Assessment
Reassess clinical status within 3-5 days. Look for:
- Decreasing stool frequency
- Improving hemodynamics
- Declining WBC count
- Resolving abdominal pain/distension
If no improvement or clinical deterioration occurs, this signals potential fulminant disease requiring escalation to high-dose vancomycin + IV metronidazole and immediate surgical consultation 3, 5.
Special Considerations
The 2021 update emphasizes that fidaxomicin is preferred when resources allow due to lower recurrence rates, though implementation depends on institutional formulary and cost considerations 2. In resource-limited settings, vancomycin 125 mg four times daily remains highly effective for severe disease 2, 1.
Bezlotoxumab (10 mg/kg IV once) can be considered as adjunctive therapy during antibiotic treatment to prevent recurrence, though data are limited when combined with fidaxomicin, and caution is warranted in patients with congestive heart failure 2.